In this review, the authors highlight that drugs promoting androgenic activity or inhibiting estrogenic activity may unmask or worsen androgenetic alopecia in genetically predisposed individuals, indicating the need for careful management in clinical settings.
June 2024 in “Computational and Structural Biotechnology Journal” This review discusses the integration of omics analyses in androgenetic alopecia research, reporting no new clinical results but suggesting that collaborative multi-omics studies may enhance understanding of AGA's pathomechanisms.
10 citations
,
September 2021 in “JAMA Dermatology” This study reports that persistent chemotherapy-induced alopecia in breast cancer patients frequently resembles androgenetic alopecia, and treatment with minoxidil, alone or with antiandrogens, improved hair density in many cases.
10 citations
,
July 2021 in “International Journal of Women’s Dermatology” In this review, the authors detailed various dermatologic adverse events associated with aromatase inhibitors in postmenopausal women and discussed strategies to potentially prevent these events, aiming to minimize interruptions in breast cancer treatment.
86 citations
,
November 2020 in “Annals of Oncology” These guidelines discuss prevention and management strategies for dermatological toxicities but report no new clinical results; they include expert recommendations for conditions like acneiform rash and hand-foot syndrome.
3 citations
,
February 2019 in “Journal of Cosmetic Dermatology” This summary reviews the conflicting reports regarding 17β‐estradiol's effects on hair follicle growth, highlighting potential estrogen receptor-mediated impacts and calling for further research.
59 citations
,
August 2018 in “The oncologist” This study found that permanent chemotherapy-induced alopecia was relatively common three years after treatment among breast cancer patients receiving adjuvant chemotherapy, particularly those on taxane-based regimens.
67 citations
,
April 2018 in “JAMA Dermatology” This study found that endocrine therapy for breast cancer is associated with a pattern of hair loss similar to androgenetic alopecia, negatively impacting quality of life despite mild severity.
31 citations
,
March 2017 in “Journal of The American Academy of Dermatology” This study observed various patterns of permanent alopecia in breast cancer patients treated with taxanes and adjuvant hormonal chemotherapy, hypothesizing disruptions in hair follicle cycles due to chemoinflammatory and hormonal factors.
7 citations
,
May 2016 in “SpringerPlus” This review suggests that treating endocrine therapy-induced hair loss in breast cancer patients with topical 5-alpha reductase inhibitors and supplements like Vitamin C and omega-3 fatty acids may be effective, but further studies are needed.
24 citations
,
November 2013 in “British Journal of Dermatology” This study found that chemotherapy in female breast cancer patients caused significant early hair loss, which began to recover three months after completion, whereas tamoxifen did not affect hair growth.
68 citations
,
May 2012 in “Annals of Oncology” This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.
140 citations
,
October 2008 in “Nature Genetics”
